Comparing the current results to its competitors, Neogen reported Revenue decrease in the 3 quarter 2026 year on year by -4.21 %, despite the revenue increase by the most of its competitors of 7.82 %, recorded in the same quarter.
Neogen's Comment on Competition and Industry Peers
Neogen operates in a competitive environment with numerous competitors, including small businesses and divisions of large multinational companies, some possessing significantly greater financial resources. The company is not aware of any single competitor pursuing a similarly broad strategy encompassing disposable tests, culture media, veterinary pharmaceuticals, and instruments addressing various food safety and animal safety concerns. Competition factors include ease of use, speed, accuracy, product performance, product line breadth, sales and customer service effectiveness, and pricing. Future competition may increase due to emerging technologies. Neogen's competitive position relies on its ability to develop proprietary products, retain qualified personnel, execute production and marketing plans, protect intellectual property, and obtain sufficient capital resources.
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.
Senestech Inc operates on a business model focused on developing and commercializing innovative technologies for managing animal populations. Their methods aim to provide non-lethal solutions for controlling fertility in target species.
Idexx Laboratories Inc operates within the veterinary diagnostics industry, offering a comprehensive suite of innovative products and services tailored for veterinary practices globally. Their business model focuses on the development and manufacture of diagnostic tests, instruments, and software solutions that assist in the detection and management of animal health issues. Revenue is primarily generated through direct sales of these products to veterinarians, clinics, and laboratories, enhancing the quality of animal care through advanced diagnostic capabilities.
Sources:
Neogen Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neogen Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
